Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

DOI Web Site Web Site 1 Citations

Journal

  • The Lancet

    The Lancet 400 (10358), 1103-1116, 2022-10

    Elsevier BV

Citations (1)*help

See more

Report a problem

Back to top